Skip to main content

Bodenstedt Matthias's Form 4 filing

MoonLake Immunotherapeutics (MLTX) · filed Dec 21, 2023

Accession no.
0001213900-23-097671
Filed
Dec 21, 2023
Trade date
Dec 19-20, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions. Open-market sales total $5.92M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bodenstedt MatthiasCIK 0001920545Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 19, 2023Class A ordinary shares, par value $0.0001 per shareSSaleDisposed−94,736$59.22F2−$5,610,265.92526,167Direct
Dec 20, 2023Class A ordinary shares, par value $0.0001 per shareSSaleDisposed−5,264$58.34F3−$307,101.76520,903Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $56.655 to $60.13. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $57.53 to $59.27. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)